| 4.58 -0.06 (-1.29%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.29 | 1-year : | 6.97 |
| Resists | First : | 5.38 | Second : | 5.96 |
| Pivot price | 4.94 |
|||
| Supports | First : | 4.44 | Second : | 3.7 |
| MAs | MA(5) : | 4.68 |
MA(20) : | 5.08 |
| MA(100) : | 5.03  |
MA(250) : | 7.37 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 16.2 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 13.31 | Low : | 3.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DTIL ] has closed above bottom band by 19.0%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.59 - 4.62 | 4.62 - 4.65 |
| Low: | 4.44 - 4.48 | 4.48 - 4.51 |
| Close: | 4.53 - 4.59 | 4.59 - 4.63 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Wed, 21 May 2025
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
Thu, 15 May 2025
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Thu, 15 May 2025
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Thu, 15 May 2025
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Thu, 15 May 2025
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 8.76e+006 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 753 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.276e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 10.4 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 894.3 % |
| Return on Equity (ttm) | -11.1 % |
| Qtrly Rev. Growth | 6.87e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 12.29 |
| EBITDA (p.s.) | 4.43226e+007 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.37 |
| Price to Cash Flow | 1.03 |
| Dividend | 0 |
| Forward Dividend | 666750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|